Zofin Plus Standard Care for COVID-19

"Research into Zofin Plus Standard Care commenced in 2020, led by Organicell Regenerative Medicine. Subsequent to the initial investigation involving 20 patients, it successfully passed through its Phase 1 & 2 clinical trial stages. At present there is one live study being sponsored by Organicell Regenerative Medicine exploring this therapeutic option."

"Unfortunately, this clinical test is not presently accepting applicants. It was initially posted on September 8th 2020 and last modified nearly two years later on the 19th of September 2022. For those seeking other trials, 1887 studies connected to Covid-19 are currently enrolling participants while one research project related to Zofin Plus Standard Care remains open for enrolment."

"At this point in time, the trial is not enrolling participants. The research initiative was first introduced on September 8th 2020 and edited lastly on September 19th 2022. If you are searching for alternative studies, 1887 clinical trials concerning COVID-19 (pathology) and 1 study about Zofin Plus Standard Care are actively recruiting patients."

"Currently, there is one ongoing clinical trial studying the efficacy of Zofin Plus Standard Care. This research project has not progressed to Phase 3 yet, though it is taking place in three different locations within New york City."

"According to the report by Organicell Regenerative Medicine, their primary objective is to measure Incidence of Severe Adverse Events over a two-month period. Secondary outcome metrics include All Cause Mortality (as assessed at day 60 or hospital discharge), Quantification of COVID-19 (through viral load analysis and nose/throat swabs) as well as Chest Imaging Changes (including Ground Glass Opacity, Local Patchy Shadowing, Bilateral Patchy Shadowing and Interstitial Abnormalities)."